Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | IDH1 R132H |
Therapy | Panobinostat + Tazemetostat |
Indication/Tumor Type | high grade glioma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | high grade glioma | sensitive | Panobinostat + Tazemetostat | Preclinical - Cell culture | Actionable | In a preclinical study, cotreatment with Tazverik (tazemetostat) sensitized mouse glioma cells expressing IDH1 R132H to Farydak (panobinostat) in culture, resulting in synergistic inhibition of cell viability (PMID: 38334611). | 38334611 |
PubMed Id | Reference Title | Details |
---|---|---|
(38334611) | EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor. | Full reference... |